AmerisourceBergen 2009 Annual Report Download - page 23

Corporate Information
SHAREHOLDER SERVICES
Our transfer agent, BNY Mellon, can help you with
a variety of shareholder services, including:
• Change of address
• Lost stock certificates
• Stock transfer
• Account consolidation
BNY MELLON CAN BE REACHED AT:
Telephone: [phone], or TDD 800-231-5469
Internet: www.bnymellon.com/shareowner/isd
Email: [e-mail]
Mail: AmerisourceBergen Corporation
c/o BNY Mellon Shareowner Services
P.O. Box 358015
Pittsburgh, PA 15252-8015
ADDITIONAL INFORMATION
Financial documents, such as our Annual Report on Form 10-K, and
quarterly reports on Form 10-Q, the Company’s Code of Ethics and
Business Conduct and other reports and filings may be obtained from
the Company website at www.amerisourcebergen.com, or by calling
the Company’s Investor Relations Department at 610-727-7429.
INVESTOR RELATIONS
Shareholders, security analysts, portfolio managers, and other investors
desiring further information about the Company should contact
Michael N. Kilpatric, Vice President, Corporate & Investor Relations
at 610-727-7118, or [e-mail].
ANNUAL MEETING
AmerisourceBergen shareholders are invited to attend our annual
meeting on March 4, 2010 at 2:00 pm Eastern Time at The Four Seasons
Hotel, One Logan Square, Philadelphia, Pennsylvania.
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Ernst & Young LLP, Philadelphia, PA
STOCK LISTING
AmerisourceBergen Corporation is listed on The New York Stock
Exchange under the symbol ABC.
Certain of the statements contained in this summary annual report are
“forward-looking statements” within the meaning of Section 27A of the Securities
Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These
statements are based on management’s current expectations and are subject
to uncertainty and change in circumstances. Among the factors that could
cause actual results to differ materially from those projected, anticipated or
implied are the following: changes in pharmaceutical market growth rates;
the loss of one or more key customer or supplier relationships; changes in
customer mix; customer delinquencies, defaults or insolvencies; supplier
defaults or insolvencies; changes in pharmaceutical manufacturers’ pricing
and distribution policies or practices; adverse resolution of any contract or
other dispute with customers or suppliers; federal and state government
enforcement initiatives to detect and prevent suspicious orders of controlled
substances and the diversion of controlled substances; qui tam litigation for
alleged violations of laws and regulations governing the marketing, sale and
purchase of pharmaceutical products; changes in U.S. legislation or regulatory
action affecting pharmaceutical product pricing or reimbursement policies,
including under Medicaid and Medicare; changes in regulatory or clinical
medical guidelines and/or labeling for the pharmaceutical products we distribute,
including certain anemia products; price inflation in branded pharmaceuticals
and price deflation in generics; significant breakdown or interruption of our
information technology systems; our inability to implement an enterprise
resource planning (ERP) system to handle business and financial processes
within AmerisourceBergen Drug Corporation’s operations and our corporate
functions without operating problems and/or cost overruns; success of
integration, restructuring or systems initiatives; interest rate and foreign
currency exchange rate fluctuations; economic, business, competitive and/or
regulatory developments in Canada, the United Kingdom and elsewhere
outside of the United States, including potential changes in Canadian provincial
legislation affecting pharmaceutical product pricing or service fees or regulatory
action by provincial authorities in Canada to lower pharmaceutical product
pricing or service fees; the impact of divestitures or the acquisition of businesses
that do not perform as we expect or that are difficult for us to integrate or
control; our inability to successfully complete any other transaction that we
may wish to pursue from time to time; changes in tax legislation or adverse
resolution of challenges to our tax positions; increased costs of maintaining,
or reductions in our ability to maintain, adequate liquidity and financing sources;
volatility and deterioration of the capital and credit markets; and other economic,
business, competitive, legal, tax, regulatory and/or operational factors affecting
our business generally. Certain additional factors that management believes could
cause actual outcomes and results to differ materially from those described
in forward-looking statements are set forth (i) in Item 1A (Risk Factors) in the
Company’s Annual Report on Form 10-K for this Fiscal Year Ended September
30, 2009 and elsewhere in that report and (ii) in other reports filed by the
Company pursuant to the Securities Exchange Act of 1934.
21